Meeting Highlights Information Registration Visa Letter Application Programme Overview Exhibition Virtual Exhibition Hotels Exhibition Virtual Exhibition Satellite Programme


Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Exposure keratopathy: Incidence and risk factors

Poster Details


First Author: R.El Hachimi MOROCCO

Co Author(s): R. El Hadiri   N. Boutimzine   W. Maazouzi   L. Cherkaoui           

Abstract Details

Purpose:

The purpose of this study is to determine the incidence of exposure keratopathy in patients in the intensive care unit and its risk factors.

Setting:

University mohamed 5 of rabat

Methods:

This is a prospective cohort study including all patients admitted to an adult intensive care unit department for five months. Patients were examined daily. Examination included assessment of lid position, conjunctival edema (chemosis) and corneal changes. keratopathy and lagophthalmia have been classified according to Mercieca's classification. Univariate and multivariate statistical analysis was done by SPSS 20.0.

Results:

Of the 91 patients included in the study, 50,4% had exposure keratopathy. 54,9% of patients developed chemosis and 35,4% developed lagophthalmia. The tear film was altered in 41,8%. 82,4% of patients were sedated. In bivariate logistic regression there are no arguments of an association between PEP and  chemosis: OR: 1.770; p value: 0.2; 95% CI: 0.738-4.243. In multivariate analysis, only chemosis (OR : 25.28, CI: 3.34-191.5) p = 0.002, lagophthalmia (OR: 40.83, IC: 4.34-383.6) p = 0.001 and the length of stay in intensive care OR: 12,28; IC: 1.47-101.23) p = 0.02 were risk factors for occurrence of exposure keratopathy.

Conclusions:

The incidence of exposure to keratopathy in intensive care patients is high, with mainly lagophthalmia, chemosis and duration of hospitalization as risk factors. However, there are no statistical arguments in favor of an association between positive expiratory pressure (PEP) and the risk of chemosis.

Financial Disclosure:

None

Back to Poster listing